



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/735,461-Conf. #3119		
		Filing Date	December 11, 2003		
		First Named Inventor	Michael P. CZECH		
		Art Unit	1635		
		Examiner Name	R. A. Schnizer		
Sheet	1	of	2	Attorney Docket Number	UMY-055

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PS	A1*	US-20020162126-A1	10-31-2002	Beach et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
PS	B1	WO-99/32619-A1	07-01-1999	The Carnegie Institute of Washington et al		
	B2	WO-99/54465-A2	10-28-1999	Warner-Lambert Company et al.		
	B3	WO-00/31291-A1	06-02-2000	Pharmacia & Upjohn AB		
	B4	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research et al		
	B5	WO-01/93669-A2	12-13-2001	Devgen NV		
PS	B6	WO-02/33046-A2	04-25-2002	University of Massachusetts		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
PS	C1	Bose, Avirup et al., "Gα11 Signaling through ARF6 Regulates F-Actin Mobilization and GLUT4 Glucose Transporter Translocation to the Plasma Membrane," <i>Molecular and Cellular Biology</i> , Vol. 21(15):5262-5275 (2001)			
I	C2	Bose, Avirup et al., "Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c," <i>Nature</i> , Vol. 420(6917):821-824 (2002)			
	C3	Czauderna, Frank et al., "Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA," <i>Nucleic Acids Research</i> , Vol. 31(2):670-682 (2003)			
	C4	Elbashir, Sayda M. et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , Vol. 26:199-213 (2002)			
I	C5	Izuishi, Kunihiro et al., "Remarkable Tolerance of Tumor Cells to Nutrient Deprivations: Possible New Biochemical Target for Cancer Therapy," <i>Cancer Research</i> , Vol. 60:6201-6207 (2000)			
	C6	Min, Jing et al., "Synip: A Novel Insulin-Regulated Syntaxin 4-Binding Protein Mediating GLUT4 Translocation in Adipocytes," <i>Molecular Cell</i> , Vol. 3:751-760 (1999)			
	C7	Paradis, Suzanne et al., " <i>Caenorhabditis elegans</i> Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor," <i>Genes & Development</i> , Vol. 12:2488-2498 (1998)			
PS	C8	Siegmund, Daniela et al., "Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis," <i>Molecular Medicine</i> , Vol. 8(11):725-732 (2002)			


Examiner Signature		Date Considered	9/25/07
-----------------------	--	--------------------	---------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/735,461-Conf. #3119
				Filing Date	December 11, 2003
				First Named Inventor	Michael P. CZECH
				Art Unit	1635
				Examiner Name	R. A. Schnizer
Sheet	2	of	2	Attorney Docket Number	UMY-055

<i>TS</i>	C9	Tuschl, Thomas et al., "Small Interfering RNAs: A Revolutionary Tool for the analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , Vol. 2(3):158-167 (2002)	
<i>TS</i>	C10	Walters, D.K. et al., "The Effectiveness of Double-Stranded Short Inhibitory RNAs (siRNAs) May Depend on the Method of Transfection," <i>Antisense and Nucleic Acid Drug Development</i> , Vol. 12:411-418 (2002)	
<i>TS</i>	C11	Weil, D. et al., "Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells," <i>BioTechniques</i> , Vol. 33(6):1244-1248 (2002)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	9/25/07
--------------------	---	-----------------	---------